ArticleThe American journal of psychiatry2019
Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode.
Erratum issuedAbstract read
In one paragraph
Article in The American journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 103 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Domain-specific cognitive function in euthymic bipolar disorder: a systematic review and meta-analysis.Psychological medicine · 2025Pooled it
- Cognitive change 5+ years since the onset of a psychotic disorder: A systematic review and meta-analysis.Psychological medicine · 2025Pooled it
- Cognitive Effects of Lurasidone and Cariprazine: A Mini Systematic Review.Current neuropharmacology · 2023Pooled it
- Enhancing Assertive Community Treatment With Cognitive Behavioral Social Skills Training for Schizophrenia: II. Ecological Momentary Assessment Outcomes in a Pragmatic Randomized-Controlled Trial.Schizophrenia bulletin · 2026Trial
- Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Reduces Variability in Brain Function in Schizophrenia: Data From a Double-Blind, Randomized, Sham-Controlled Trial.Schizophrenia bulletin · 2025Trial
- A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- The impact of early intervention for first episode psychosis on cognitive functioning.Schizophrenia research · 2023Trial
- Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial.Translational psychiatry · 2023Trial
- The BDNF-mediated association between NGAL and cognitive function in drug-naïve schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Cognitive impairment and associated white matter organization abnormalities across the illness course of schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Cognitive impairment preceding the onset of the first psychosis episode in schizophrenia.Molecular psychiatry · 2026Review
- Mendelian-Randomization Study Reveals Causal Relationships Between Blood Metabolites and Psychiatric Disorders.Schizophrenia bulletin · 2026Article
- Genome-wide pleiotropic analysis identifies shared genetic architecture within the cognition-immune nexus.Translational psychiatry · 2026Article
- Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials.Acta psychiatrica Scandinavica · 2026Review
- Rethinking language, cognition and assessment in psychosis: How bilingualism challenges psychiatry and how natural language processing can help.Schizophrenia (Heidelberg, Germany) · 2026Review
- Screening for Cognitive Decline in Psychotic Disorders in Midlife: Examining Scoring the Clinical Dementia Rating Using Longitudinal Data.Schizophrenia bulletin · 2026Article
- Neurocognitive function in schizophrenia spectrum disorders: A 20-year prospective study of a community sample.Schizophrenia research. Cognition · 2026Article
- Does neurocognition predict personal recovery over time in psychotic disorder patients?Schizophrenia research. Cognition · 2026Article
- Premorbid functioning trajectories and the one-year course of cognitive performance in first-episode psychosis: a cluster analysis in PSYSCAN.Schizophrenia research. Cognition · 2026Article
- Clarifying Fundamental Role of Symbol Coding in Cognitive Networks in Schizophrenia and Healthy Controls Leveraging Gaussian Graphical Models and Bayesian Networks.Schizophrenia bulletin · 2026Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
14 authors.
Jolanta ZanelliThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Josephine MollonThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Sven SandinThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Craig MorganThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Paola DazzanThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Izabela PileckaThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Tiago Reis MarquesThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Anthony S DavidThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Kevin MorganThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Paul FearonThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Gillian A DoodyThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Peter B JonesThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Robin M MurrayThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Abraham ReichenbergThe Department of Psychosis Studies (Zanelli, Dazzan, Pilecka, Reis Marques, David, Murray, Reichenberg) and the Department of Psychology (Pilecka), Institute of Psychiatry, Psychology, and Neuroscience, King's College London; the Department of Psychiatry, Harvard Medical School, Boston (Mollon); the Department of Psychiatry (Sandin, Reichenberg), the Department of Environmental Medicine and Public Health, and the Friedman Brain Institute (Reichenberg), Icahn School of Medicine at Mount Sinai, New York; the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (Sandin); the Centre for Public Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (C. Morgan); the Department of Psychology, University of Westminster, London (K. Morgan); the Department of Psychiatry, Trinity College, Dublin (Fearon); the Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, U.K. (Doody); and the Department of Psychiatry, University of Cambridge, Cambridge, U.K., and the Institute of Mental Health, University College London (Jones).
Funding
Medical Research Council MC_PC_11003Medical Research Council MR/S003444/1MRF_ C0439
Abstract
objectiveSchizophrenia is associated with a marked cognitive impairment that is widely believed to remain stable after illness onset. Yet, to date, 10-year prospective studies of cognitive functioning following the first episode with good methodology are rare. The authors examined whether schizophrenia patients experience cognitive decline after the first episode, whether this decline is generalized or confined to individual neuropsychological functions, and whether decline is specific to schizophrenia.
methodsParticipants were from a population-based case-control study of patients with first-episode psychosis who were followed prospectively up to 10 years after first admission. A neuropsychological battery was administered at index presentation and at follow-up to patients with a diagnosis of schizophrenia (N=65) or other psychoses (N=41) as well as to healthy comparison subjects (N=103).
resultsThe schizophrenia group exhibited declines in IQ and in measures of verbal knowledge and of memory, but not processing speed or executive functions. Processing speed and executive function impairments were already present at the first episode and remained stable thereafter. The magnitude of declines ranged between 0.28 and 0.66 standard deviations. Decline in measures of memory was not specific to schizophrenia and was also apparent in the group of patients with other psychoses. Healthy individuals with low IQ showed no evidence of decline, suggesting that a decline is specific to psychosis.
conclusionsPatients with schizophrenia and other psychoses experience cognitive decline after illness onset, but the magnitude of decline varies across cognitive functions. Distinct mechanisms consequent to the illness and/or psychosocial factors may underlie impairments across different cognitive functions.
Indexed as
AdultCase-Control StudiesCognition DisordersFemaleHumansIntelligence TestsMaleNeuropsychological TestsProspective StudiesPsychotic DisordersSchizophreniaSchizophrenic PsychologyTime FactorsCognitive NeurosciencePsychosisSchizophrenia
Identifiers
PMID
31256609What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.